This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Osiris, Arena, Ampio

GVHD is a potentially deadly complication stemming from bone marrow transplants in which transplanted immune cells attack a patient's own organs and tissue as foreign.

I previously predicted that Osiris would not be successful in gaining Canadian approval for Prochymal as a treatment for GVHD. Obviously I was wrong, but with an asterisk because newly released documents show that Health Canada granted conditional approval to Prochymal out of compassion for children with a very rare fatal illness and not based on convincing scientific evidence.

The Health Canada documents -- a summary report on an expert advisory panel that reviewed Prochymal and the drug's Canadian-approved label -- show that the decision to approve the stem cell therapy was based on clinical data culled in part from a failed study found to be "limited" and "suggestive but not definitive with respect to efficacy" by the Canadian agency's expert advisors.

This is how the six-member Expert Advisory Panel on Prochymal summed up Procyhmal's efficacy data:

"The panel noted that severe Grade D GvHD is an extremely serious disease that affects a very small patient population. A few panel members have seen in their clinical experience how pediatric patients dramatically responded to treatment with Prochymal. However, this positive anecdotal evidence is not adequately reflected in the efficacy data.

"The panel further noted that there is very limited efficacy data; the data is suggestive but not definitive with respect to efficacy. There is a very small post-hoc analysis (in children) from a randomized [sic] trial, protocol 280 that demonstrated a small change in effects between the Prochymal arm and the placebo arm. In addition, protocol 275 is a cohort study for severe refractory GvHD with limited efficacy endpoints and vague inclusion criteria. In protocol 275, the survival probability through 180 days post onset of acute GvHD in refractory Grade D pediatric patients is 56.2% for the Prochymal group and 31% for the historical control group. From a clinical perspective, this is a positive effect; however, it is not a conclusive indication of efficacy."

Despite lack of convincing evidence, the advisory panel, which met Jan. 26 under the auspices of Health Canada, deemed Prochymal to be safe and "most probably effective" for a small group of severely ill patients (kids with GVHD) who had run out of medical treatment options.
2 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ARNA $1.57 0.00%
AMPE $2.10 0.00%
OSIR $6.39 0.00%
VVUS $1.02 0.00%
AAPL $94.02 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs